Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Total Debt (2016 - 2023)

Arcadia Biosciences' Total Debt history spans 10 years, with the latest figure at $15000.0 for Q1 2023.

  • For Q1 2023, Total Debt fell 78.26% year-over-year to $15000.0; the TTM value through Mar 2023 reached $15000.0, down 78.26%, while the annual FY2022 figure was $48000.0, 25.0% down from the prior year.
  • Total Debt reached $15000.0 in Q1 2023 per RKDA's latest filing, down from $48000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $3.2 million in Q4 2020 to a low of $12000.0 in Q1 2019.
  • Average Total Debt over 5 years is $700882.4, with a median of $114000.0 recorded in 2021.
  • Peak YoY movement for Total Debt: soared 14447.37% in 2020, then crashed 98.0% in 2021.
  • A 5-year view of Total Debt shows it stood at $147000.0 in 2019, then soared by 2080.27% to $3.2 million in 2020, then plummeted by 98.0% to $64000.0 in 2021, then fell by 25.0% to $48000.0 in 2022, then tumbled by 68.75% to $15000.0 in 2023.
  • Per Business Quant, the three most recent readings for RKDA's Total Debt are $15000.0 (Q1 2023), $48000.0 (Q4 2022), and $47000.0 (Q3 2022).